Background Previous studies have suggested that primary prophylaxis against pneumocystis pneumonia (PCP) using trimethoprim-sulfamethoxazole (TMP-SMX) is beneficial in patients with rheumatologic diseases receiving immunosuppressive drugs [1] . However, there little evidence for an optimal duration or a time point of withdrawal. Objectives This study aims to investigate the risk factors are ass...